Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

RNC Pharma Database Update: Pharmaceutical Drug Production in Russia (June 2018)

Tuesday, July 31, 2018

Between January and June 2018, Russia produced 157.4 bln RUB worth of pharmaceutical drugs (dispatch prices, VAT included), which is in monetary terms 1.2% lower than that of the same period of 2017. In physical terms, Russia produced 2 bln units of pharmaceuticals over the period, which is 10% lower than that of the same period of 2017. If calculated in minimum dosage units (MDU), the dynamics are +0.6%. The dynamics of the production of over-the-counter drugs in physical terms are -9%, while those of the Rx production are -11%. In June, the dynamics of the OTC production were +4.5%, while those of the Rx production were -19%.

Among the top 10 EphMRA groups of level two with the highest dispatch volume of OTC drugs in physical terms, 7 have negative dynamics. Antivirals, painkillers and cough and cold medicines are among the worst, with -32%, -19% and -15%, respectively. Nose medicines have the highest dynamics in the groups with a sales increase, especially Oxyfrin (Groteks) and Evamenol (Moscow Pharmaceutical Factory), with a 47% increase.

As for Rx drugs, the following categories have the lowest dynamics: solutions for intravenous admission (-50%), anti-infective drugs (-19%), and anti-inflammatory and anti-rheumatics drugs (-15%). Nevertheless, the production of beta-adrenoblockers has very good dynamics (+52%), in particular Sotalol (Canonpharma Production) (+100%) and Nebivolol (Severnaya Zvezda) (+56%.)

Read more about pharmaceutical drug production in Russia (April results) here: http://rncph.com/news/29_06_2018

Dynamics of pharmaceutical drug production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (units) and monetary terms (RUB, VAT included) (January 2017 – June 2018)

Share: